William Blair is concerned about the company's transition from drug development to commercialization.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
They're the most important executive at most small developmental or early commercialization concerns.
Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.
Analyst at William Blair says Allakos is a leader in research for a treatment for a rare stomach disease.
The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.
Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.